PK-DB: pharmacokinetics database for individualized and stratified computational modeling

Jan Grzegorzewski1, Janosch Brandhorst1, Kathleen Green2, Dimitra Eleftheriadou1, Yannick Duport3, Florian Barthorscht1, Adrian Köller1, Danny Yu Jia Ke4, Sara De Angelis5 and Matthias König1,*

1Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany, 2Department of Biochemistry, University of Stellenbosch, Van der Byl Street, Stellenbosch 7600, South Africa, 3Department of Mathematics and Computer Science, Freie Universität Berlin, Arnimallee 14, Berlin 14195, Germany, 4Department of Biology, University of Ottawa, Ottawa, ON, Canada and 5King’s College London, Department of Biomedical Engineering & Imaging Sciences, London, UK

Received August 23, 2020; Revised October 01, 2020; Editorial Decision October 12, 2020; Accepted November 03, 2020

ABSTRACT

A multitude of pharmacokinetics studies have been published. However, due to the lack of an open database, pharmacokinetics data, as well as the corresponding meta-information, have been difficult to access. We present PK-DB (https://pk-db.com), an open database for pharmacokinetics information from clinical trials. PK-DB provides curated information on (i) characteristics of studied patient cohorts and subjects (e.g. age, bodyweight, smoking status, genetic variants); (ii) applied interventions (e.g. dosing, substance, route of application); (iii) pharmacokinetic parameters (e.g. clearance, half-life, area under the curve) and (iv) measured pharmacokinetic time-courses. Key features are the representation of experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, a workflow for collaborative data curation, strong validation rules on the data, computational access via a REST API as well as human access via a web interface. PK-DB enables meta-analysis based on data from multiple studies and data integration with computational models. A special focus lies on meta-data relevant for individualized and stratified computational modeling with methods like physiologically based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD), or population pharmacokinetic (pop PK) modeling.

INTRODUCTION

The pharmacokinetics (PK) of drugs and medication, i.e. how the body after administration affects substances via absorption, distribution, metabolization, and elimination, are of great interest for medical research and drug development. The main measures in the field are concentration-time profiles and derived PK parameters from these time-courses like half-lifes or clearance rates. These measures strongly depend on the dosage and individual characteristics of the subject or group under investigation. Factors like age, weight, sex, smoking behavior, genetic variants or disease drive the large inter-individual variability in PK (1) making such meta-data indispensable for research in pharmacokinetics. The study of variability in drug exposure due to these covariates is an important field of research with a long history, generally referred to as population pharmacokinetics (2). Modern approaches go beyond classical population information by accounting for additional factors, for example, for genetic variants (3). This meta-information on subjects in combination with the main measures are the basis for individualized and stratified approaches in drug treatment which will potentially pave the road towards both precision dosing and precision medicine.

A multitude of PK studies have been published but despite the wealth of literature almost none of the data is accessible in a machine-readable format and certainly not with FAIR (findable, accessible, interoperable and reproducible) principles (4) in mind. The lack of transparency and reproducibility (5) in the field is ubiquitous. Currently the only way to retrieve this treasure is by digitizing and curating the pharmacokinetics information from publications. Despite the central role of PK in the medical and pharma field, no open freely accessible database of pharmacokinetics information exists so far. In addition, heterogeneity in the reporting of clinical study designs, pharmacokinetic measures, in-
PK-DB (https://pk-db.com) is an open web-accessible database storing comprehensive information on pharmacokinetics studies consisting of PK data, PK parameters, and associated meta-information (see Figure 1 for a general overview).

**Database statistics**

PK-DB provides curated information on (i) characteristics of studied patient cohorts and subjects (e.g. age, bodyweight, smoking status, genetic variants); (ii) applied interventions (e.g. dosing, substance, route of application); (iii) concentration-time curves and (iv) parameters measured in PK studies (e.g. clearance, half-life and area under the curve). The focus so far of data curation has been on substances applied in dynamical liver function tests, benzodiazepines, statins, and studies of glucose metabolism.

PK-DB-v0.9.3 (9) consists of 512 studies containing 1457 groups, 6308 individuals, 1408 interventions, 73 017 outputs, 3148 time-courses and 37 scatters related to acetaminophen, caffeine, codeine, diazepam, glucose, midazolam, morphine, oxazepam, simvastatin or torasemide (see Figure 2, Supplementary Material 1 and Supplementary Material 2).

**Design principles**

Important features of PK-DB are the representation of experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, a workflow for collaborative data curation, strong validation rules on the data, computational access via a REST API as well as human access via a web interface. Key principles in the design of PK-DB were:

**Accessibility of data for computational modeling and data science.** All data is available via REST endpoints as well as the web frontend allowing for simple integration of PK-DB data into existing workflows, e.g. for the building of computational models. The REST web service allows querying and retrieving all information from PK-DB in an automatic fashion. The major advantage of the REST API (https://pk-db.com/api/v1/swagger/) as a central access point is that it can be accessed programmatically independent of the programming language. In the following, we present various use cases to demonstrate the usefulness of this approach, e.g. creating an overview of the database content using R and circos (Figure 2), and meta-analyses of multiple studies using Python (Figure 4). The use of PK-DB data is facilitated by annotation of biological and medical concepts to respective ontologies. This enables the integration with additional data sets or computational models based on the semantic information, e.g., substances are annotated to ChEBI (10), and diseases to ncit, hp, doid and mondo (11–14). A special focus lies on meta-data for individualized and stratified computational modeling of pharmacokinetics with methods like physiologically based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD) or population pharmacokinetic (pop PK) modeling.

**Extensibility and generalizability.** The PK-DB data model is not limited to a specific problem domain but allows simple extensions to other fields and experimental data sets, within the overall area of pharmacokinetics. Examples are extensible types for the group or individual characteristics currently represented in the database. Additional types can easily be added to cover the important information for a given problem domain.

**Unit and data normalization.** A key challenge in using data for computational modeling and data science are non-standardized units coming from different data sets. It requires time-consuming retrieval of this information from

Figure 1. PK-DB overview. Schematic overview of the curation process and interaction with the PK-DB database. Data is either extracted from literature (digitization of figures and tables) or data sets are directly imported (from collaboration partners). Figure panels, data sets, meta-data and study information on subjects, interventions and dosing is curated. All data files and the study information are uploaded via REST endpoints. The curated data is checked against validation rules, data is normalized (e.g. units), and pharmacokinetic parameters are calculated. The uploaded study information can either be programmatically accessed via the REST API or via the web frontend.

individual, and population-related meta-information further complicates data reuse and integration. Many studies only report a small fraction of the underlying data, e.g. individual data or prominent PK parameters are missing in most studies and even time-courses averaged over subjects within a group are only present in a subset of data.

For computational modeling, meta-analysis and most methods in machine learning a standardized and machine-readable representation of data is of major importance. PK data could be utilized in many different ways (6–8) if such a representation and corresponding database would exist. One of the various applications is pharmacokinetic modeling which provides a unique opportunity to integrate PK data and parameters from multiple clinical trials into a single predictive model.

These models can integrate PK-DB data on differences in the study protocol, the dosing, as well as individual, group and population characteristics and be parameterized and validated with the available time courses and pharmacokinetic parameters.

**DESCRIPTION AND RESULTS**

PK-DB is a database storing comprehensive information on pharmacokinetics studies consisting of PK data, PK parameters, and associated meta-information (see Figure 1 for a general overview).
Figure 2. PK-DB content. (A) Studies. Overview of the study content in PK-DB. PK-DB-v0.9.3 (9) 512 studies containing 1457 groups, 6308 individuals, 1408 interventions, 73017 outputs, 3148 time-courses and 37 scatters related to acetaminophen, caffeine, codeine, diazepam, glucose, midazolam, morphine, oxazepam, simvastatin or torasemide. The circular plot is structured in stripes and rings, with each stripe representing a single study. In each ring, the counts of different data types are depicted. Dot size corresponds to the number of entries. The rings give an overview of the following information (1) name of the study; (2) number of outputs (PK parameters and other measurements). Red dots represent reported data, blue dots data calculated from time-courses; (3) number of time-courses; (4) number of participants. Purple dots represent participants with individual data, green dots represent participants which are reported as a group; (5) the number of interventions applied to the participants in the study. (B) Substances Overview of the substance content in PK-DB. Substances with very few entries (<2 studies) are excluded from the plot. The circular plot is structured in stripes and rings, with each stripe representing a different substance. Substances were clustered in five substance classes (caffeine, glucose, codeine, and paracetamol) by agglomerative clustering of the pair co-occurrence of substances within studies. Classes are labeled according to the most frequent substance within the class. Each co-occurrence of two substances is visualized by a connecting ribbon between the substances in the center. The rings describe the following information for the respective substance (1) name of the substance; (2) number of outputs (PK parameters and other measurements). Red dots represent reported data and blue dots represent data calculated from reported concentration-time profiles. (3) the number of time-courses; (4) number of applied interventions; (5) number of studies in which the substance occurred. For complete figures see Supplementary Material 1 and Supplementary Material 2.

Non-compartmental methods were chosen for comparison of calculated values with reported PK parameters in the literature, mainly calculated based on non-compartmental methods.

Data quality. Strong validation (e.g. of categoricals), minimum relevant information, instance cross-referencing and correct unit-dimensions ensure high quality of the curated data. Non-obvious curation mistakes (or respective errors in the reporting of the data) can be addressed by outlier identification in subsequent meta-analyses.

Access rights. PK-DB allows to keep studies privately or only share with certain collaborators. This allows sharing the study during the curation process only with trusted people with a simple option to make the study public. Some information is only accessible by a limited group of users due to copyright issues, e.g. for manually curated studies from the literature the underlying publication can only be made accessible if it is Open Access. A subset of studies is currently private because the underlying raw data from the clinical trial has not been published yet.
Calculation of pharmacokinetic parameters

An important part of PK-DB is the automatic calculation of PK parameters from the reported concentration-time curves based on non-compartmental methods (15). Figure 3 and Table 1 illustrate the automatic calculation of PK parameters from concentration-time profiles for an example study. The authors were hereby interested in the influence of specific genetic alleles on the pharmacokinetics of codeine (16). In the study, information was limited to the averaged measures with variation (standard error within group), but no individual subject data was reported.

Calculated parameters are the area under the curve (AUC\textsubscript{end}), the area under the curve extrapolated to infinity (AUC\textsubscript{∞}), the concentration maximum (C\textsubscript{max}), the time at concentration maximum (t\textsubscript{max}), the half-life (t\textsubscript{half}), the elimination rate (k\textsubscript{el}), the clearance (Clearance) and the volume of distribution (V\textsubscript{d}). The calculated values are in good agreement with the reported values (all lie within the reported standard deviations).

Mathematically correct, first the PK parameters should be calculated for each subject individually and subsequently be averaged. Unfortunately, this is not possible if only averaged data is reported. Consequently, as approximation PK parameters are calculated on the averaged time-courses. Due to the often very large inter-individual differences in pharmacokinetics the calculated values on average data can be notable different between reported and calculated parameters (Table 1, e.g. t\textsubscript{half}). Even more fundamentally, the description of the data as averages with variations has inherent problems by assuming homogeneity of the data which often is not the case (17). Consequently, we strongly encourage the publication of individual subject data in PK studies.

A further limitation of PK studies is that often only a subset of pharmacokinetics information is reported. In the example displayed in Table 1 (16), the volume of distribution (V\textsubscript{d}) and the elimination rate (k\textsubscript{el}) are not reported, but can be calculated.
Figure 4. Meta-analysis of caffeine clearance depending on caffeine dose. Caffeine clearance is stratified based on reported smoking and oral contraceptive (OC) use. UNKNOWN (grey) data corresponds to unreported smoking and OC, CONTROL (green) are non-smokers not taking OC, SMOKING (blue) are smokers not taking OC, OC (dark orange) are non-smokers taking OC, and OC-SMOKING (light orange) are smokers taking oral contraceptives. For the stratification groups the number of individuals (I), number of groups (G) and number of total participants (TP) is provided in the legend. Individual and group data is depicted, with group size encoded as dot size. Data points from groups are labeled by the study identifier. Reported PK parameters are depicted as circles, PK parameters calculated from concentration-time profiles as squares, and PK parameters inferred from PK data and reported bodyweights of the participants as triangles (to convert to dose per bodyweight). Typically, dosing is reported in mass units and clearance in a volume per time. Sometimes both values are reported in bodyweight units. Here, all available data is harmonized. Suspicious data from four studies (18–21), very likely from a single clinical trial, was excluded.

Meta-analysis of caffeine

PK-DB allowed us for the first time to undertake an extensive and systematic analysis of the effect of lifestyle factors like smoking and oral contraceptive use on the clearance of caffeine combining data from multiple studies. For this use case, we integrated data from 44 studies, based on programmatic interaction with PK-DB via the REST API. By curating information about the respective patient characteristics (lifestyle factors), the actual interventions performed in the studies (dosing and route), and important information like the errors on the reported data we could gain a unique view on the strong and consistent effect of smoking and oral contraceptive use on the clearance of caffeine. The large variability between studies and individuals could be markedly reduced by accounting for lifestyle information.

Importantly, the meta-analysis allowed us to directly improve the curation status of many studies by easily detecting visible outliers in the data which could in most cases directly be backtracked to curation errors or incorrectly reported data (e.g. incorrect units) which were subsequently corrected in the database.

A positive aspect is that most of the reported studies are consistent. For instance with caffeine, most of the data was in line with each other with a single exception being Stille et al. (18). Here, a systematic bias in the data could be observed probably due to an analytic problem. Interestingly,
Table 1. Calculation of pharmacokinetic parameters. Comparison of PK parameters for morphine reported in a representative study of codeine application (16) (see https://pk-db.com/data/PKDB00111). PK parameters were calculated from mean concentration-time profiles (see Figure 3). Only data for the groups, no individual data was reported in the study.

| Parameter (unit) | Genotype | Reported | PK-DB | Difference (%) |
|-----------------|----------|----------|-------|----------------|
| AUC<sub>end</sub> (ng/ml · h) | *1/*1 | 6.63 ± 2.07 | 6.24 | −5.88 |
| AUC<sub>inf</sub> (ng/ml · h) | *1/*10 | 3.77 ± 1.93 | 3.80 | −0.80 |
| | *10/*10 | 2.65 ± 1.95 | 2.59 | 2.26 |
| C<sub>max</sub> (ng/ml) | *1/*1 | 5.05 ± 3.30 | 3.97 | 21.39 |
| | *10/*10 | 3.26 ± 2.43 | 2.68 | 18.79 |
| t<sub>1/2</sub> (h) | *1/*1 | 2.06 ± 0.89 | 1.64 | 20.39 |
| | *10/*10 | 0.96 ± 0.42 | 0.73 | 23.96 |
| t<sub>max</sub> (h) | *1/*1 | 9.40 ± 11.70 | 4.15 | 55.85 |
| | *10/*10 | 11.50 ± 11.10 | 4.76 | 38.61 |
| k<sub>el</sub> (/h) | *1/*1 | 6.84 ± 5.46 | 4.66 | 31.87 |
| | *10/*10 | 0.64 ± 0.28 | 0.50 | 21.88 |
| k<sub>y</sub> | *1/*1 | 0.86 ± 0.52 | 0.50 | 41.86 |
| | *10/*10 | 0.86 ± 0.52 | 1.00 | −16.28 |
| | *1/*10 | 0.17 | − |
| | *10/*10 | 0.15 | − |

Reported PK parameters are presented as mean ± standard deviation (SD). Unreported values displayed as (−).

Data quality and validation

The integration of data from multiple studies and subsequent meta-analyses is a valuable procedure to identify cura-
tion errors which cannot be caught by validation rules alone. The combination of both, the validation rules and the meta-analyses helped to identify errors also in the reporting. In the following, we will give some examples of suspicious reported data detected by meta-analysis: Wang et al. (22) reported incorrect units; Seng et al. (23) calculated volumes per bodyweight incorrectly; in the publication of Carbo et al. (24) participant number 4 has a suspiciously high half-life and participant number 3 a suspiciously high clearance rate. It is unclear if this is a reporting error; In the publication of Beach et al. (25) nine smokers and two non-smokers have suspiciously very high clearance rates, again unclear if this is a reporting error. In the publication of Wu et al. (16) the concentration-time profiles and concentration maxima were reported with incorrect units.

Data validation and data integration via PK-DB allowed us to identify and correct these issues.

CONCLUSION AND DISCUSSION

PK-DB is the first open database for pharmacokinetics data and corresponding meta-information. We provide an important resource which allows storing pharmacokinetics information in a FAIR (findable, accessible, interoperable and reproducible) manner (4).

PK-DB is supported by the Federal Ministry of Education and Research (BMBF, Germany) within the re-
search network Systems Medicine of the Liver (LiSyM) until 2021. PK-DB is a central part of the DFG funded project QuaLiPerf (Quantifying Liver Perfusion–Function Relationship in Complex Resection—A Systems Medicine Approach) with maintenance guaranteed until end of 2025.

We demonstrate the value of PK-DB via a stratified meta-
analyses of pharmacokinetics studies for caffeine curated from literature which allows us to integrate and harmonize pharmacokinetics information from a wide range of studies and sources. By performing the curation for commonly applied drugs (codeine and paracetamol), for a substance used in liver function tests (caffeine), as well as for glucose we could demonstrate the applicability of PK-DB to a wide range of substances and gain insights into how well data is reported in the various fields.

PK-DB has many unique features compared to existing databases for pharmacokinetics information, such as the database for pharmacokinetics properties (26) or the recent pharmacokinetic database time-series data and parameters for 144 environmental chemicals (27). PK-DB allows to handles experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, comes with a workflow for collaborative data curation, has strong validation rules on the data, and provides computational access via a REST API as well as human access via a web interface.

The reporting of data in the field of pharmacokinetics is very poor despite the main point of the publications being the reporting of the data. Without guidelines on minimal information for studies, it is very difficult to compare studies or integrate data from different sources. Incomplete and poor reporting of data in the field of pharmacokinetics has also been reported by others (28,29). As our analysis shows, even basic information, crucial for the interpretation and analyses of PK studies, are not reported in many publications. It is impossible to integrate and reuse such data. For instance, in the case of codeine, often not even the given dose can be retrieved from the publication because it is not clearly reported which substance was administered (codeine-sulfate, codeine-phosphate or codeine). Other examples are unreported bodyweights, so that conversions to doses per bodyweight are not possible.

Based on our work we have a set of important suggestions when publishing clinical studies in the field of pharma-
cokinetics: (i) Publish the actual data in a machine-readable format (e.g. a data table in the supplement); (ii) Publish the actual concentration-time curves, not only derived parameters; (iii) Provide data for individual subjects which is much more informative and allows to calculate all data for individuals and for groups; (iv) Provide at minimum information on (individual) patient characteristics which includes basic anthropometric information like age, bodyweight, sex, height, and the subset of important lifestyle factors known to alter pharmacokinetics (e.g. co-medication, oral contraceptive use, smoking status, alcohol consump-
tion or for instance for CYP1A2 substrates like caffeine: methylxanthine consumption/abstinence); (v) Clearly de-
scribe the study protocol: Which substance was given in which dose, in which route (oral, intravenous), and in what form (tablet, capsule, solution).
Prospective plans for PK-DB are to increase the scope by manual curation and semi-automatic approaches. Furthermore, workflows for the deposition of pharmacokinetics data upon publication will be established.

We envision that PK-DB will encourage better reporting of pharmacokinetics studies by providing means for data representation and integration and will improve reusability of pharmacokinetics information by providing PK data in a central database, and will facilitate data integration between studies and with computational models.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

Author contributions: J.G. and M.K. conceived the study, drafted the manuscript, implemented the software, and performed all analyses. J.G., M.K., J.B., K.G., Y.D., F.B., A.K., D.K., S.D.A. and D.E. curated data for PK-DB. All authors read, corrected and approved the manuscript.

FUNDING

J.G. and M.K. are supported by the Federal Ministry of Education and Research (BMBF, Germany) within the research network Systems Medicine of the Liver (LiSyM, 031L0054); BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) [031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B]. Funding for open access charge: Federal Ministry of Education and Research (BMBF, Germany) within the research network Systems Medicine of the Liver (LiSyM, 031A537C, 031A534A, 031A532B].

Conflict of interest statement.

REFERENCES

1. Polasek, T.M., Shakib, S. and Rostami-Hodjegan, A. (2018) Precision dosing in clinical medicine: present and future. Expert. Rev. Clin. Immu., 11, 743–746.
2. Aarons, L. (1991) Population pharmacokinetics: theory and practice. Brit. J. Clin. Pharmac., 23, 669–670.
3. Lötsch, J., Skarke, C., Schmidt, H., Rohrbacher, M., Hofmann, U., Schwab, M. and Geisslinger, G. (2006) Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin. Pharmac. Th., 79, 35–48.
4. Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J.J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L.B., Bourne, P.E. et al. (2016) The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018.
5. Ioannidis, J.P.A. (2019) Reproducible pharmacokinetics. J. Pharmacokinet. Phar., 46, 111–116.
6. Mould, D.R. and Upton, R.N. (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT: Pharmacometrics Syst. Pharmacol., 1, 66.
7. Mould, D.R. and Upton, R.N. (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT: Pharmacometrics Syst. Pharmacol., 2, 383.
8. Upton, R.N. and Mould, D.R. (2014) Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT: Pharmacometrics Syst. Pharmacol., 3, 388.
9. König, M. and Grzegorzek-Swi, J. (2020) mathiaskoe nig/pkdb: release notes for pkdb-v0.9.3.
10. Hastings, J., Owen, G., Dekker, A., Ennis, M., Kale, N., Muthukrishnan, V., Turner, S., Swainston, N., Mendes, P. and Steinbeck, C. (2016) ChEBI in 2016: improved services and an expanding collection of metabolites. Nucleic Acids Res., 44, D1214–D1219.
11. Sioutos, N., de Coronado, S., Haber, M.W., Hartel, F.W., Shain, W.-L. and Wright, L.W. (2007) NCT Thesaurus: a semantic model integrating cancer-related clinical and molecular information. J. Biomed. Inform., 40, 30–43.
12. Köhler, S., Carmody, L., Vasilevska, N., Jacobsen, J.O.B., Danis, D., Gourdin, J.-P., Gargano, M., Harris, N.L., Matentzoglou, N., McMurry, J.A. et al. (2019) Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res., 47, D1018–D1027.
13. Kibbe, W.A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C.J., Binder, J.X., Malone, J., Vasant, D. et al. (2015) Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data. Nucleic Acids Res., 43, D1071–D1078.
14. Mungall, C.J., McMurry, J.A., Köhler, S., Balhoff, J.P., Berroame, C., Brush, M., Carbon, S., Conlin, T., Dunn, N., Engelstad, M. et al. (2017) The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res., 45, D712–D722.
15. Gabrielson, J. and Weiner, D. (2012) Non-compartmental analysis. Methods Mol. Biol. (Clifton, N.J.), 929, 377–389.
16. Wu, X., Yuan, L., Zuo, J., Lv, J. and Guo, T. (2014) The Impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects. Eur. J. Clin. Pharmacol., 70, 57–63.
17. Hanin, L. (2017) Why statistical inference from clinical trials is likely to generate false and irreproducible results. BMC Med. Res. Methodol., 17, 127.
18. Stille, W., Harder, S., Mieke, S., Beer, C., Shah, P.M., Frech, K. and Staib, A.H. (1987) Decrease of caffeine elimination in man during co-administration of 4-quinolones. J. Antimicrob. Chemoth., 20, 729–734.
19. Harder, S., Staib, A.H., Beer, C., Papenburg, A., Stille, W. and Shah, P.M. (1988) 4-Quinolones inhibit biotransformation of caffeine. Eur. J. Clin. Pharmacol., 35, 651–656.
20. Harder, S., Fuhr, U., Staib, A.H. and Wolf, T. (1989) Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am. J. Med., 87, 895–918.
21. Balogh, A., Harder, S., Vollandt, R. and Staib, A.H. (1992) Intra-individual variability of caffeine elimination in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 383–387.
22. Wang, T., Kleger, G., Stellaard, F. and Pumgartner, G. (1985) Caffeine elimination: a test of liver function. Klin. Wochenschr., 63, 1124–1128.
23. Seng, K.-Y., Fun, C.-Y., Law, Y.-L., Lim, W.-M., Fan, W. and Lim, C.-L. (2009) Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. J. Clin. Pharm. Ther., 34, 103–114.
24. Carbó, M., Segura, J., De la Torre, R., Badenas, J.M. and Camí, J. (1989) Effect of quinolones on caffeine disposition. Clin. Pharm. Th., 45, 234–240.
25. Beach, C.A., Mays, D.C., Guiler, R.C., Jacober, C.H. and Gerber, N. (1986) Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin. Pharm. Th., 39, 265–270.
26. Moda, T.L., Torres, L.G., Carrara, A.E. and Andricopulo, A.D. (2008) PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics (Oxford, England), 24, 2270–2271.
27. Sayre, R.R., Wambaugh, J.F. and Gruke, C.M. (2020) Database of pharmacokinetic time-series data and parameters for 144 environmental chemicals. Scientific Data, 7, 122.
28. Kanji, S., Haynes, M., Ling, A., Samuel, L., Chant, C., Edwards, D.J., Edwards, S., Ensom, M.H.H., Foster, D.R., Hardy, B. et al. (2015) Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin. Pharmacokinet., 54, 783–795.
29. Dykstra, K., Mehrotra, N., Tornoe, C.W., Kastrissios, H., Patel, B., Al-Huniti, N., Jadhav, P., Wang, Y. and Byon, W. (2015) Reporting guidelines for population pharmacokinetic analyses. J. Pharmacokinet. Phar., 42, 301–314.